Open AccessDevelopment of surface engineered mesoporous alumina nanoparticles: drug release aspects and cytotoxicity assessment
Author(s) -
More Mahesh P.,
Ganguly Payal R.,
Pandey Abhijeet P.,
Dandekar Prajakta P.,
Jain Ratnesh D.,
Patil Pravin O.,
Deshmukh Prashant K.
Publication year - 2017
Publication title -
iet nanobiotechnology
Language(s) - English
Resource type - Journals
ISSN - 1751-875X
DOI - 10.1049/iet-nbt.2016.0225
Subject(s) - repaglinide , nanoparticle , poloxamer , ammonium bromide , nuclear chemistry , materials science , chemical engineering , scanning electron microscope , fourier transform infrared spectroscopy , nanotechnology , chemistry , pulmonary surfactant , composite material , medicine , polymer , endocrinology , type 2 diabetes , engineering , copolymer , diabetes mellitus
The present investigation deals with successful synthesis and surface functionalisation of mesoporous alumina (MeAl) nanoparticles by simplified sol–gel method using cetyl trimethyl ammonium bromide (CTAB) and pluronic as a template. Surface functionalisation of MeAl was performed to determine the selectivity of surface groups for coupling with model drug molecule. Repaglinide a BCS class II drug was loaded as a model drug on synthesised MeAl nanoparticle and studied for its sustained release capability. The synthesised and repaglinide loaded MeAl nanoparticles were characterised by Fourier transform infrared Spectroscopy, X‐ray diffraction, field emission scanning electron microscopy with EDAX, Transmission electron microscopy and differential scanning calorimetric. Results from the dissolution study confirmed the sustained release behaviour of the nanparticles which was up to 24 h. The cell viability assay demonstrated that 0.2 to 1 mg/ml concentration of MeAl was significantly less cytotoxic to the Chinese Hamster Ovary (CHO) cells. The authors’ experimental studies suggest that MeAl can be used as drug carrier and have a potential to increase the stability, loading efficiency and patient compliance for poorly water‐soluble drugs such as repaglinide.